Total votes: 12

Cash Balance Dec 31st 2009:  A$23.7 million

ASX and OTCQX listed

Commercial relationships include: Dade Behring (Siemens), SSL (Durex condoms), Elanco (Eli Lilly), EMD Merck, Sigma Aldrich, Stiefel Inc., Qiagen

Largest shareholders include: Dow Chemical Co., Acorn, Platinum LLC; ~22% US shareholding

Starpharma Holdings Limited is an Australia-based company engaged in the development and commercialization of dendrimer products for pharmaceutical, life-science and other applications. Activities within the Company are directed towards the development of nano-scale materials, with a particular focus on the development of its topical vaginal microbicide, VivaGel, for the prevention of genital herpes and human immunodeficiency virus (HIV), and the application of dendrimers to drug delivery and other life science applications.

It is also engaged in exploring dendrimer opportunities in materials science with applications in areas, such as adhesives, lubricants and water remediation. The activities are managed by the Company’s wholly owned subsidiaries Starpharma Pty Ltd. in Melbourne and Australia, and Dendritic Nanotechnologies (DNT), Inc. in Michigan, United States.

The company predicts the world’s first herpes-killing vaginal gel may go on sale by 2012 and they plan to start patient studies on its effectiveness for genital herpes in 2010-11. Chief Executive Officer Jackie Fairley said in an interview in Singapore, declining to identify the partners. The Melbourne-based company licensed its VivaGel- coated condoms in 2008 to SSL International Plc, maker of the world’s best-selling Durex brand.

Possible upcoming Events:

- seeking public funding for separate studies of VivaGel aimed at preventing Herpes & HIV infection in 2010

- start studies on their product’s effectiveness against bacterial vaginosis, the most common vaginal infection in women of childbearing age, later in 2010

- studies on genital herpes prevention in 2010-11